VALBIOTIS
Regulatory News:
VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / PEA/SME eligible), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, today announced the presentation of a preclinical study conducted by the CarMeN laboratory on the active substance TOTUM-63, at the 55th Annual Meeting of the European Association for the Study of Diabetes being held September 16-20, 2019 in Barcelona, Spain.
This preclinical study evaluated the effect of TOTUM-63 on the secretion of certain hormones which play a fundamental role in glucose metabolism. In a murine model of metabolic disease, TOTUM-63 completely corrected insulin, glucagon and GLP-1 (Glucagon-Like Peptide-1) concentrations in the portal vein, in response to a glucose intake. These three hormones are central to the regulation of blood glucose.
This study confirms, via an independent laboratory, the effects already demonstrated1 on blood glucose and weight by TOTUM-63, the active substance of VALEDIA® , a product designed to control blood glucose in prediabetics.
Béatrice MORIO-LIONDORE*, Research Director at the CarMeN Research Laboratory, comments: "We are delighted to be presenting this study at the 55th EASD Annual Meeting. The results obtained demonstrate the significant effects of TOTUM-63 on weight and glucose metabolism in this preclinical model. In addition, our study aimed to evaluate the effect of TOTUM-63 on the hormonal imbalances associated with metabolic diseases. We have proven that TOTUM-63 corrects the blood levels of three key hormones in glucose metabolism: insulin and glucagon, secreted by the pancreas, as well as GLP- 1, an intestinal hormone essential for blood glucose control that is well-known in the field of diabetes."
Pascal SIRVENT, Head of Discovery and Preclinical and Translational Research at VALBIOTIS adds: "The results obtained by the CarMeN laboratory team have high value for VALBIOTIS: by examining the hormonal level, this study has made a fundamental contribution to increasing our understanding of the action of TOTUM-63 on metabolism. The hormonal effects reported today are consistent with the improvement in metabolic parameters that have already been widely observed, both in preclinical and clinical studies with TOTUM-63. These results provide clear evidence of the positive action of TOTUM-63 on the levels of hormones whose secretion is altered in prediabetes or diabetes. "
The poster of this study is available on the VALBIOTIS website: https://www.valbiotis.com/en/scientific-publications/
ABOUT THE CARMEN LABORATORY
The CarMeN laboratory - INSERM U1060 / INRA U1397 / INRA U1397 / Lyon1 University / INSA Lyon (directed by Hubert VIDAL) is a biomedical research laboratory in the fields of cardiovascular diseases, metabolism, diabetes and nutrition. It is a center of excellence, based in Lyon, that brings together the leading minds in research in the fields of metabolism, nutrition and cardiovascular diseases. With approximately 180 collaborators, including researchers, teachers and hospital practitioners, the CarMeN laboratory is supported by state-of-the-art technological (genomics, lipidomics, imaging) and clinical (CRNH, CIC) research platforms, providing a unique environment for conducting valuable translational research.
*Béatrice MORIO-LIONDORE is INRA Research Director for Team 3 ("Organelle communication and diabetes" headed by Jennifer RIEUSSET and Charles THIVOLET) of the CarMeN research laboratory and previously led a team working on obesity in the Human Nutrition Unit in Clermont-Ferrand. She has published more than 90 articles and journals.
About TOTUM-63, the active ingredient of VALEDIA®
Prediabetes is a growing public health problem worldwide, recognized by international organizations such as the WHO, the American Diabetes Association and the International Diabetes Federation, among others. Without effective treatment, 70% to 90% of prediabetic patients will develop type 2 diabetes.
VALEDIA® is the first clinically validated product specifically designed to help prediabetics reduce their risk of developing type 2 diabetes. VALEDIA® is the only product that contains the active ingredient TOTUM-63, a unique and patented combination of 5 plant extracts that act in synergy to target the physiopathological mechanisms of type 2 diabetes.
TOTUM-63 has already shown perfect tolerance and safety during a Phase I/II clinical study conducted in healthy volunteers. The results of the Phase IIA international randomized, placebo-controlled study showed that in patients with prediabetes, TOTUM-63 reduces fasting blood glucose and blood glucose at 2 hours, two risk factors of type 2 diabetes. In these subjects, who also presented with hypertriglyceridemia and abdominal obesity, TOTUM-63 significantly reduced body weight, waist circumference, blood triglycerides, blood LDL cholesterol, Fatty Liver Index and arterial hypertension.
ABOUT VALBIOTIS
VALBIOTIS is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases. Its products are made for major players in the health care sector. VALBIOTIS particularly focuses on solutions to prevent type 2 diabetes, NASH (nonalcoholic steatohepatitis), obesity and cardiovascular diseases.
VALBIOTIS was founded in La Rochelle in early 2014 and has formed numerous partnerships with top academic centers in France and abroad, including La Rochelle University, the CNRS and Clermont Auvergne University located in Clermont-Ferrand. These partnerships have enabled VALBIOTIS to benefit from strong financial leverage thanks to experts and technical partners who support its projects. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63) – and an American office in Boston (MA).
VALBIOTIS is a member of the "BPI Excellence" network and received the "Innovative Company" status accorded by BPI France. VALBIOTIS has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs by obtaining support from the European Regional Development Fund (ERDF). VALBIOTIS is a PEA-SME eligible company.
Find out more about VALBIOTIS:
www.valbiotis.com
Name: VALBIOTIS
ISIN code: FR0013254851
Mnemonic code: ALVAL
Disclaimer
This press release contains forward-looking statements about VALBIOTIS' objectives. VALBIOTIS considers that these projections are based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and doubts, including those described in the VALBIOTIS registration document, filed with the French Financial Markets Regulator (AMF) on 31 July 2019 (application number R 19-030). This document is available on the Company's website (www.valbiotis.com ). VALBIOTIS does not accept any liability regarding the update or revision of these forward-looking statements.
This press release, as well as the information contained herein, does not constitute an offer to sell or subscribe to, or a solicitation to purchase or subscribe to, VALBIOTIS' shares or securities in any country.
1 See press release of 3 July 2019: https://www.valbiotis.com/app/uploads/2019/07/2019-06-21-PR_VALBIOTIS_PHASEIIA-VALEDIA.pdf
View source version on businesswire.com: https://www.businesswire.com/news/home/20190916005618/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Klarna Launches Tap to Pay for In-Store Purchases Across 14 Markets2.12.2025 09:00:00 CET | Press release
Klarna, the global digital bank and flexible payments provider, today launches the brand new feature Tap to Pay across 14 European markets, bringing flexible payments into physical retail at scale and transforming the Klarna app into an everyday contactless wallet. With more than 80% of European shopping still happening in physical stores, Tap to Pay brings consumers the ease of online shopping into the bricks and mortar stores. Instead of hunting for cards or juggling apps, everything sits in one place — the Klarna app — making every purchase smoother from start to finish. Utilising NFC technology, Tap to Pay turns the Klarna app into a contactless wallet, letting consumers set up a flexible payment plan and pay with a tap, all in one place – without adding their card to another wallet or switching apps at checkout. Tap to Pay builds on the rapid global uptake of the new debit-first Klarna Card, now used by more than 4 million consumers. The card is debit by default, with the option t
SkillOnNet Redefines RNG Gaming with World-First Launch of AI-Powered GAIA Roulette2.12.2025 09:00:00 CET | Press release
GAIA is the world’s first AI-driven roulette host now in commercial use. Global entertainment brand SkillOnNet has announced the launch of GAIA Roulette, a groundbreaking new roulette experience powered by artificial intelligence. The game – which is now live on PlayUZU Mexico, with plans to expand to additional markets across the SkillOnNet network in the coming months – blends the thrill of RNG gameplay with the 3D realism of a live dealer. It’s the world’s first AI-driven roulette host now in commercial use. Unlike traditional RNG tables, GAIA Roulette features an intelligent, interactive digital dealer that is personalized to each player. GAIA learns player preferences, adapts its communication style, and provides real-time assistance, helping users understand bets, game flow, and strategies. Players can discuss game events – asking questions about game results, previous numbers, their wins and losses, and review gameplay history – but they can also talk about everyday topics like
Expedition Growth Capital Raises $375 Million Fund III in First and Final Close2.12.2025 09:00:00 CET | Press release
Fund III is Expedition’s third consecutive fund closed at the hard cap The London and Boston-based firm specialises in minority growth equity investments in domain-expert software & AI companies with a use but not a need for capital Expedition Growth Capital (“Expedition”), a software-specialist growth equity firm, today announced that it has raised its third fund of $375 million, continuing its focus on partnering with rapidly growing companies from across Europe that have built high-quality products and customer bases, without venture capital. The oversubscribed raise was completed in four months, with more than half of commitments from US investors, including leading endowments and foundations. Since its founding in late 2020, Expedition has built a portfolio of 17 bootstrapped software leaders from nine European countries, the majority already operating in North America. Portfolio companies include Dougs, a Lyon-based AI-powered accounting solution used by over 30,000 businesses, e
Payments Modernisation: Gap Between Confidence and Readiness Among Industry Leaders Widens, ACI Worldwide Study Finds2.12.2025 08:00:00 CET | Press release
69% of payments executives see their organisations as leaders, yet fewer than half prioritise innovation as legacy systems and internal resistance slow progress Payments leaders remain confident about the pace of industry innovation, but many risk falling behind as expectations accelerate. New global research from ACI Worldwide (NASDAQ: ACIW) and Globant reveals a widening gap between confidence and readiness that could define industry leadership in 2026 and beyond. The report Payments in Transition: Leadership in an era of transformation, based on a survey of 500 industry leaders across North America, Europe, Latin America, Middle East & Africa, and Asia Pacific, shows that while 69% of executives consider their organisations to be payments leaders, fewer than half (44%) say payments innovation is a C-suite priority. This disconnect is driven by barriers that will become increasingly costly in the year ahead. More than half (55%) of executives admit they are not fully using the techno
Oulu Launches Its European Capital of Culture Year with a Three-day Opening Festival2.12.2025 07:00:00 CET | Press release
The Oulu2026 Opening Festival on 16–18 January 2026 transforms the city centre into a vibrant celebration of culture, community and northern creativity. It marks the beginning of a historic year and invites residents, visitors and partners from Finland, Europe and beyond to take part in a unique moment for Oulu and its 39 partner municipalities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251201071170/en/ In January, Oulu’s city centre will transform into the Oulu2026 Opening Festival area. Photo: Harri Tarvainen / City of Oulu image bank. “After years of preparation, Oulu2026 is finally here. The Opening Festival gives everyone a chance to be part of something that will only happen once, and it all begins in the heart of Oulu,” says Piia Rantala-Korhonen, CEO of Oulu2026. Almost 200 events, over 20 venues The Opening Festival presents a wide range of art and cultural experiences all over the city centre. From exhibitions
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom